

# CITATION REPORT

List of articles citing

Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation

DOI: 10.1016/j.jaad.2017.06.043

Journal of the American Academy of Dermatology,  
2018, 78, 383-394.

**Source:** <https://exaly.com/paper-pdf/69191870/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #  | Paper   | IF  | Citations |
|----|---|-----|-----------|
| 61 | The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. <i>Mucosal Immunology</i> , <b>2018</b> , 11, 1558-1570  | 9.2 | 46        |
| 60 | Inflammatory bowel disease: Looking beyond the tract. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2019</b> , 33, 2058738419866567   | 3   | 14        |
| 59 | A Rare Case of New-Onset Ulcerative Colitis following Initiation of Secukinumab. <i>Case Reports in Medicine</i> , <b>2019</b> , 2019, 2975631  | 0.7 | 4         |
| 58 | State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. <i>Current Opinion in Pharmacology</i> , <b>2019</b> , 46, 90-99   | 5.1 | 24        |
| 57 | Association of psoriasis/psoriatic arthritis with inflammatory bowel disease influences management strategy. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33, e431-e432 <sup>2</sup>   | 4.6 | 4         |
| 56 | [Dermatologic Manifestations in Inflammatory Bowel Disease]. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , <b>2019</b> , 73, 285-293   | 0.6 | 2         |
| 55 | Psoriasis and Inflammatory Bowel Disease. <i>Digestive Diseases</i> , <b>2019</b> , 37, 451-457   | 3.2 | 19        |
| 54 | Bacterial Dysbiosis and Translocation in Psoriasis Vulgaris. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2019</b> , 9, 7   | 5.9 | 47        |
| 53 | Study on the effect of spleen deficiency on the pathogenesis of psoriasis based on intestinal microbiome. <i>Longhua Chinese Medicine</i> , <b>2019</b> , 2, 14-14  | 0.3 | 0         |
| 52 | [Guselkumab]. <i>Annales De Dermatologie Et De Venereologie</i> , <b>2019</b> , 146, 515-519  | 0.3 |           |
| 51 | Interleukin-17: Potential Target for Chronic Wounds. <i>Mediators of Inflammation</i> , <b>2019</b> , 2019, 1297675   | 4.3 | 10        |
| 50 | TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , <b>2019</b> , 4, 70-80  | 1.1 | 33        |
| 49 | Ixekizumab for the treatment of psoriasis: an update on new data since first approval. <i>Expert Review of Clinical Immunology</i> , <b>2019</b> , 15, 111-121  | 5.1 | 15        |
| 48 | Crohn's disease exacerbated by IL-17 inhibitors in patients with psoriasis: a case report. <i>BMC Gastroenterology</i> , <b>2020</b> , 20, 340  | 3   | 5         |
| 47 | The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment. <i>Scandinavian Journal of Immunology</i> , <b>2020</b> , 92, e12946   | 3.4 | 8         |
| 46 | Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2). <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 1914-1923 | 4.6 | 8         |
| 45 | Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review. <i>Journal of Dermatological Treatment</i> , <b>2020</b> , 1-8   | 2.8 | 3         |

|    |   |      |    |
|----|---|------|----|
| 44 | Skin Manifestations in Pediatric Patients Treated With a TNF-Alpha Inhibitor for Inflammatory Bowel Disease: A Retrospective Study [Formula: see text]. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2020</b> , 24, 333-339  | 1.6  | 5  |
| 43 | Is Psoriasis Treatment a Risk Factor for Inflammatory Bowel Disease?. <i>Pharmaceutical Medicine</i> , <b>2020</b> , 34, 257-262  | 2.3  | 5  |
| 42 | Safety update of etanercept treatment for moderate to severe plaque psoriasis. <i>Expert Opinion on Drug Safety</i> , <b>2020</b> , 19, 439-448   | 4.1  | 7  |
| 41 | The safety of brodalumab for the treatment of psoriasis. <i>Expert Opinion on Drug Safety</i> , <b>2020</b> , 19, 365-372   | 4.1  | 6  |
| 40 | Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. <i>Annals of Oncology</i> , <b>2020</b> , 31, 724-744  | 10.3 | 64 |
| 39 | Clinical Profile of Melkersson-Rosenthal Syndrome/Orofacial Granulomatosis: A Review of 51 Patients. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2021</b> , 25, 390-396   | 1.6  | 3  |
| 38 | EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, 281-317  | 4.6  | 19 |
| 37 | Maintaining Clinical Freedom Whilst Achieving Value in Biologics Prescribing: An Integrated Cross-Specialty Consensus of UK Dermatologists, Rheumatologists and Gastroenterologists. <i>BioDrugs</i> , <b>2021</b> , 35, 187-199  | 7.9  | 2  |
| 36 | Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review. <i>American Journal of Clinical Dermatology</i> , <b>2021</b> , 22, 425-442  | 7.1  | 13 |
| 35 | Guidelines for Management of Psoriasis. <i>Journal of the Dermatology Nurses Association</i> , <b>2021</b> , 13, 168-174  | 4.2  | 1  |
| 34 | New possibilities of systemic therapy of plaque psoriasis with the IL23p19 inhibitor risankizumab. <i>Meditsinskiy Sovet</i> , <b>2021</b> , 40-50  | 0.4  |    |
| 33 | Qinzhuiliangxue mixture alleviates psoriasis-like skin lesions via inhibiting the IL6/STAT3 axis. <i>Journal of Ethnopharmacology</i> , <b>2021</b> , 274, 114041   | 5    | 0  |
| 32 | Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> ,                              | 4.5  | 3  |
| 31 | German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 2: Treatment monitoring and specific clinical or comorbid situations. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2021</b> , 19, 1092-1115                              | 1.2  | 3  |
| 30 | Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm - Teil 2: Therapiemonitoring, besondere klinische Situationen und Komorbiditat. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2021</b> , 19, 1092-1117                          | 1.2  | 5  |
| 29 | Risk of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis initiating interleukin 17 inhibitors: a nationwide population-based study using the French national health data system. <i>Arthritis and Rheumatology</i> , <b>2021</b> , | 9.5  | 8  |
| 28 | Early prescription of biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An expert opinion. <i>Sovremennaya Revmatologiya</i> , <b>2020</b> , 14, 7-18   | 0.7  | 3  |
| 27 | Psoriasis and inflammatory bowel diseases: pathogenetic pathways and the choice of biologic therapy (a literature review). <i>Al'manah Kliničeskoj Mediciny</i> , <b>2019</b> , 47, 568-578   | 0.2  | 7  |

|    |   |     |    |
|----|---|-----|----|
| 26 | Psoriasis: a personalized approach to therapy. The preferred choice of systemic agents considering comorbid pathologies. <i>Meditinskiy Sovet</i> , <b>2020</b> , 28-34   | 0.4 | 2  |
| 25 | Brodalumab in psoriasis: evidence to date and clinical potential. <i>Drugs in Context</i> , <b>2019</b> , 8, 212570   | 5.2 | 33 |
| 24 | Early administration of genetically engineered biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An experts opinion. <i>Almanah Kliničkoj Mediciny</i> , <b>2020</b> , 48, 422-436  | 0.2 | 5  |
| 23 | COMPLEX TREATMENT THE PATIENTS WITH PSORIASIS AND CONCOMITANT ACTIVATED HERPES VIRUS INFECTION, TYPES 1, 2. <i>Wiadomości Lekarskie</i> , <b>2020</b> , 73, 1968-1972   | 0.3 |    |
| 22 | Adalimumab for Psoriasis. <b>2021</b> , 153-172   |     |    |
| 21 | Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits. <i>Journal of Clinical and Aesthetic Dermatology</i> , <b>2019</b> , 12, 46-54  | 1.2 | 3  |
| 20 | Choosing the right biologic for complications of inflammatory bowel disease.. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2022</b> ,   | 4.2 | 1  |
| 19 | How to Choose the Biologic Therapy in a Bio-naïve Patient with Inflammatory Bowel Disease.. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11,   | 5.1 | 1  |
| 18 | Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2 - Management of Special Populations, Patients With Comorbid Conditions, and Risk.. <i>Actas Dermosifiliográficas</i> , <b>2022</b> ,           | 0.5 | 1  |
| 17 | A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II.. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> ,  | 6.1 | 4  |
| 16 | Temporal Relationship of Extraintestinal Manifestations in Inflammatory Bowel Disease.. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,   | 5.1 | 1  |
| 15 | Effective topical treatments of innovative NNO-tridentate vanadium (IV) complexes-mediated photodynamic therapy in psoriasis-like mice model. <i>Journal of Materials Chemistry B</i> ,   | 7.3 | 0  |
| 14 | Data_Sheet_1.pdf. <b>2019</b> ,   |     |    |
| 13 | Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 2 Manejo de poblaciones especiales, pacientes con comorbilidad y gestión del riesgo. <i>Actas Dermosifiliográficas</i> , <b>2022</b> , | 0.5 | 0  |
| 12 | Gut inflammation induced by drugs: Can pathology help to differentiate from inflammatory bowel disease?. <i>United European Gastroenterology Journal</i> ,  | 5.3 | 0  |
| 11 | Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. <i>Frontiers in Immunology</i> , 13,   | 8.4 | 7  |
| 10 | Part I: Interactive case: Psoriasis. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , <b>2022</b> , 5, 644-648   | 1.4 |    |
| 9  | Comorbidity in Adult Psoriasis: Considerations for the Clinician. <i>Psoriasis: Targets and Therapy</i> , Volume 12, 139-150  | 2.4 | 0  |

|   |   |     |
|---|---|-----|
| 8 | Melkersson-Rosenthal syndrome in children and adolescents: a series of seven cases. <i>Anais Brasileiros De Dermatologia</i> , <b>2022</b> ,                | 1.6 |
| 7 | Correlation of HLA-Cw6 Positivity with Clinical Characteristics and Treatment Efficacy in Korean Patients with Psoriasis. <b>2022</b> , 34, 253             | ○   |
| 6 | An update on emerging immunological targets and their inhibitors in the treatment of psoriasis. <b>2022</b> , 113, 109341                                   | ○   |
| 5 | A shared tissue transcriptome signature and pathways in psoriasis and ulcerative colitis. <b>2022</b> , 12,   | ○   |
| 4 | Seronegative spondyloarthritis-associated inflammatory bowel disease. 29, 450-468   | ○   |
| 3 | Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities. <b>2023</b> , 37, 35-55                           | ○   |
| 2 | ANALYSIS OF THE EFFICACY AND SAFETY OF GENETICALLY ENGINEERED BIOLOGICAL THERAPY FOR MODERATELY SEVERE AND SEVERE FORMS OF PSORIASIS. <b>2022</b> , 19, 3-9 | ○   |
| 1 | Mendelian Randomization Studies in Psoriasis and Psoriatic Arthritis: A Systematic Review. <b>2023</b> , 143, 762-776.e3                                    | ○   |